Literature DB >> 31420886

Nonimmune hydrops fetalis and congenital disorders of glycosylation: A systematic literature review.

Mona M Makhamreh1, Naiga Cottingham2, Carlos R Ferreira3, Seth Berger3, Huda B Al-Kouatly1.   

Abstract

Numerous etiologies may lead to nonimmune hydrops fetalis (NIHF) including congenital disorders of glycosylation (CDG). Recognition of CDG in NIHF is challenging. This study reviews prenatal and neonatal characteristics of CDG presenting with NIHF. A systematic literature search was performed. Thirteen articles met the inclusion criteria. Twenty-one cases with NIHF associated with a CDG were reported. There were 17 live births, three pregnancy terminations, and one fetal demise. Timing of CDG diagnosis was reported mostly postnatally (90%; 10/11). Postnatal genetic testing was reported in 18 patients; three patients were diagnosed by isoelectric focusing of serum transferrin that showed a type 1 pattern. The genes reported for CDG with NIHF for 15 distinct families include: PMM2 in 47% (7/15), ALG9 in 20% (3/15), ALG8 in 13% (2/15), ALG1 in 7% (1/15), MGAT2 in 7% (1/15), and COG6 7% (1/15). In our review, 81% (17/21) reported facial dysmorphism, 52% (11/21) reported CNS abnormalities, most commonly cerebellar atrophy (64%; 7/11), and 38% (8/21) reported cardiovascular abnormalities, most commonly hypertrophic cardiomyopathy (63%; 5/8). Among live births, 71% (12/17) infants died at a median age of 34 days (range 1-185). Thrombocytopenia was reported in 53% (9/17) patients. Of those who survived past the neonatal period, 80% (4/5) had significant reported developmental delays. CDG should be on the differential diagnosis of NIHF in the presence of cerebellar atrophy, hypertrophic cardiomyopathy, or thrombocytopenia. Our review highlights the poor prognosis in infants with NIHF due to CDG and demonstrates the importance of identifying these disorders prenatally to guide providers in their counseling with families regarding pregnancy management. SYNOPSIS: Poor prognosis in fetuses and infants with nonimmune hydrops fetalis due to congenital disorders of glycosylation highlights the importance of prenatal diagnosis of this disorder.
© 2019 SSIEM.

Entities:  

Keywords:  congenital disorders of glycosylation; nonimmune hydrops fetalis

Mesh:

Substances:

Year:  2019        PMID: 31420886     DOI: 10.1002/jimd.12162

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  5 in total

1.  ALG8-CDG: Molecular and phenotypic expansion suggests clinical management guidelines.

Authors:  Daniah Albokhari; Bobby G Ng; Alis Guberinic; Earnest James Paul Daniel; Nicole M Engelhardt; Rita Barone; Agata Fiumara; Livia Garavelli; Gabriele Trimarchi; Lynne Wolfe; Kimiyo M Raymond; Eva Morava; Miao He; Hudson H Freeze; Christina Lam; Andrew C Edmondson
Journal:  J Inherit Metab Dis       Date:  2022-06-30       Impact factor: 4.750

2.  Clinical, biochemical and molecular phenotype of congenital disorders of glycosylation: long-term follow-up.

Authors:  Anna Bogdańska; Patryk Lipiński; Paulina Szymańska-Rożek; Aleksandra Jezela-Stanek; Dariusz Rokicki; Piotr Socha; Anna Tylki-Szymańska
Journal:  Orphanet J Rare Dis       Date:  2021-01-06       Impact factor: 4.123

3.  Immune dysfunction in MGAT2-CDG: A clinical report and review of the literature.

Authors:  Sheri A Poskanzer; Matthew J Schultz; Coleman T Turgeon; Noemi Vidal-Folch; Kris Liedtke; Devin Oglesbee; Dimitar K Gavrilov; Silvia Tortorelli; Dietrich Matern; Piero Rinaldo; James T Bennett; Jenny M Thies; Irene J Chang; Anita E Beck; Kimiyo Raymond; Eric J Allenspach; Christina Lam
Journal:  Am J Med Genet A       Date:  2020-10-12       Impact factor: 2.802

4.  Liver Involvement in Congenital Disorders of Glycosylation and Deglycosylation.

Authors:  Patryk Lipiński; Anna Bogdańska; Piotr Socha; Anna Tylki-Szymańska
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

Review 5.  Platelets and Defective N-Glycosylation.

Authors:  Elmina Mammadova-Bach; Jaak Jaeken; Thomas Gudermann; Attila Braun
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.